Compare SRRK & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | ESNT |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2018 | 2013 |
| Metric | SRRK | ESNT |
|---|---|---|
| Price | $44.36 | $58.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $56.17 | ★ $67.29 |
| AVG Volume (30 Days) | ★ 1.0M | 719.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | N/A | ★ 0.73 |
| EPS | N/A | ★ 1.82 |
| Revenue | N/A | ★ $1,260,935,000.00 |
| Revenue This Year | N/A | $1.12 |
| Revenue Next Year | $534.24 | $3.37 |
| P/E Ratio | ★ N/A | $32.08 |
| Revenue Growth | N/A | ★ 1.45 |
| 52 Week Low | $27.07 | $55.22 |
| 52 Week High | $52.19 | $67.09 |
| Indicator | SRRK | ESNT |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 47.45 |
| Support Level | $42.52 | $56.70 |
| Resistance Level | $48.23 | $61.98 |
| Average True Range (ATR) | 2.10 | 1.18 |
| MACD | -0.36 | 0.10 |
| Stochastic Oscillator | 14.24 | 55.16 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.